Infliximab biosimilar - LG Life Sciences

Drug Profile

Infliximab biosimilar - LG Life Sciences

Alternative Names: LBIM-0101; TNFmab

Latest Information Update: 07 Oct 2013

Price : $50

At a glance

  • Originator LG Life Sciences
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 31 Dec 2012 Preclinical development is ongoing in South Korea
  • 31 Dec 2008 Preclinical trials in Rheumatoid arthritis in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top